Peter C Farrell (Director) sold ~$520K of ResMed|
Planned saleWant the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 2, 2026 · Filed Feb 4, 2026
The CFO of ResMed| sold $257K of ResMed| shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$257,030
Shares × reported transaction price
4 days after results of Jan 29, 2026, 87 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $254.74 on Feb 2, 2026, 25% above its 52-week low and 13% below its high, after a 4% rise over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 56% of the way up, from 251 adjusted closes. 30 trading days earlier: $245.94 on Dec 17, 2025. Describes the past only, not a forecast
RSI 52, 1% under its 200-day average, 1% above its 50-day average, 13% below the 52-week high, 20-day volatility 20% a year, against the S&P 500: +4 points over 1 month, −1 points over 3 months, −21 points over 6 months
From the adjusted closes up to Feb 2, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.3% | +0.8% | −2.1% |
| 30 days | −3.9% | −2.0% | −1.9% |
| 90 days | −21.0% | +5.5% | −26.4% |
| 180 days | −18.2% | +10.4% | −28.6% |
Past results only. Not a forecast.
Peter C Farrell (Director) sold ~$520K of ResMed|
Planned saleBrett Sandercock (Chief Financial Officer) sold ~$254K of ResMed|
Planned saleFund moves
44 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 17, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.